
Dr. Ben Bikman discusses the differences between new oral GLP-1 medications and their implications for metabolic health.
Question? 📢 Ask Dr. Bikman’s Digital Mind (multilingual): https://benbikman.com/ben-bikmans-digital-ai-mind 📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions. Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released. Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change…
Host: Dr. Ben Bikman
Organizations: Insulin IQ
Products: oral semaglutide, Orforglipron
Explore listener stats, chart rankings, contacts and more on the The Metabolic Classroom with Dr. Ben Bikman podcast page.